Affiliation:
1. AvidBiotics Corporation, 300 Utah Avenue, South San Francisco, CA 94080
2. U.S. Department of Agriculture, Agricultural Research Service, Western Regional Research Center, Produce Safety and Microbiology Unit, 800 Buchanan Street, Albany, California 94710
Abstract
ABSTRACT
Some strains of
Pseudomonas aeruginosa
produce R-type pyocins, which are high-molecular-weight phage tail-like protein complexes that have bactericidal activity against other
Pseudomonas
strains. These particles recognize and bind to bacterial surface structures via tail fibers, their primary spectrum determinant. R-type pyocins kill the cell by contracting a sheath-like structure and inserting their hollow core through the cell envelope, resulting in dissipation of the cellular membrane potential. We have retargeted an R-type pyocin to
Escherichia coli
O157:H7 by fusing a tail spike protein from an O157-specific phage, φV10, to the pyocin tail fiber. The φV10 tail spike protein recognizes and degrades the O157 lipopolysaccharide. This engineered pyocin, termed AVR2-V10, is sensitive and specific, killing 100% of diverse
E. coli
O157:H7 isolates but no other serotypes tested. AVR2-V10 can kill
E. coli
O157:H7 on beef surfaces, making it a candidate agent for the elimination of this pathogen from food products. All rare AVR2-V10-resistant mutants isolated and examined have lost the ability to produce the O157 antigen and are expected to have compromised virulence. In addition,
E. coli
O157:H7 exposed to and killed by AVR2-V10 do not release Shiga toxin, as is often the case with many antibiotics, suggesting potential therapeutic applications. The demonstration that a novel R-type pyocin can be created in the laboratory by fusing a catalytic tail spike from the family
Podoviridae
to a tail fiber of a member of the family
Myoviridae
is evidence that the plasticity observed among bacteriophage tail genes can, with modern molecular techniques, be exploited to produce nonnatural, targeted antimicrobial agents.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference33 articles.
1. Ahn, C. K., E. Klein, and P. I. Tarr. 2008. Isolation of patients acutely infected with Escherichia coli O157:H7: low tech, highly effective prevention of hemolytic uremic syndrome. Clin. Infect. Dis.46:1197-1199.
2. Cooley, M., D. Carychao, L. Crawford-Miksza, M. T. Jay, C. Myers, C. Rose, C. Keys, J. Farrar, and R. E. Mandrell. 2008. Incidence and tracking of E. coli O157:H7 in a major produce production region in California. PLoS One2:e1159.
3. Tight regulation, modulation, and high-level expression by vectors containing the arabinose PBAD promoter
4. Haas, H., T. Sacks, and N. Saltz. 1974. Protective effect of pyocin against lethal Pseudomonas aeruginosa infections in mice. J. Infect. Dis.129:470-472.
5. Enterohemorrhagic
Escherichia coli
O157:H7
gal
Mutants Are Sensitive to Bacteriophage P1 and Defective in Intestinal Colonization
Cited by
103 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献